CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 200 enrolled
Drug / intervention
1% tenofovir geldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00111943
NCT00111943Phase 2Completed
CompareCT.gov

Phase II Expanded Safety and Acceptability Study of the Vaginal Microbicide 1% Tenofovir Gel

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted May 27, 2005·Updated Nov 1, 2021

In Brief

A Phase 2 clinical trial evaluating 1% tenofovir gel for HIV Infections and Hepatitis B, Chronic. Completed, enrolled 200 participants across 3 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine the safety and acceptability of a vaginal microbicide in HIV uninfected sexually active women. Study hypothesis: The vaginal microbicide 1% tenofovir will be safe and well tolerated in HIV uninfected women who are in good general health.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Hepatitis B, Chronic
CountriesIndia, United States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH)

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 27, 2005
Study CompletionOct 1, 2007
TodayJul 2, 2026
Posted 21.1 years ago

Interventions

1% tenofovir geldrug